Melbourne, Florida

Nursing Program

MEDICATION LOG
Student Name: Jacqueline Greer
Date: 07/15/2015
Client's Initials
FC
Diagnosis: Parkinson s Disease, Dementia CCE w/Behavioral Disturbances, Hyperlipidemia
Medication: Brand and Generic
Names
Recommended Dose, Freq. and
Route
aspirin (Bayer)

Classification

Rm #: 22-A
Allergies: None

Prescribed
Dose

Prescribed
Freq.

Prescribed
Route

Antiplatelet

81 mg

Every Day

PO

Inhibits platelet
aggregation. High
serum salicylate
concentrations can
impair hepatic
synthesis of blood
coagulation factors
VII, IX, and X.

Unspecified
Cardiovascular
Disorder

Monitor lab tests: frequent PT and IRN with

concurrent anticoagulant therapy. Monitor for
salicylate toxicity; s/sx sensation of fullness in the
ears, tinnitus, and decreased or muffled hearing
are the most frequent symptoms associated with
chronic salicylate overdose. Note: Potential for
toxicity is high in older adults and patients with
asthma, nasal polyps, perennial vasomotor
rhinitis, hay fever, or chronic urticaria.

atorvastatin calcium, (Lipitor)

PO, start with 10-40 mg daily,
may increase up to 80mg/day.

Antilipemic;
HMG-CoA
reductase
inhibitor

10 mg

Bedtime

PO

Inhibitor of
reductase HMGCoA enzyme,
(essential to hepatic
cholesterol
production)

Hyperlipidemia

Monitor: for effectiveness (reduction of

LDL-C levels), digoxin toxicity with
concurrent use, pre-diabetics and diabetics
for glycemic control. Labs: lipid levels w/in
2-4 wk. post initiation and in dose, LFTs
at 6 and 12 wk. post initiation and in
dose. Assess for muscle pain, tenderness, or
weakness, if present, monitor CPK level
(d/c if marked CPK or myopathy).

calcium carbonate (Caltrate)

PO 12 g b.i.d. or t.i.d.

Fluid and
Electrolytic
Replacement
Solution; Antacid

600 mg

TID

PO

Decreases gastric
acidity, thereby
inhibiting proteolytic
action of pepsin on
gastric mucosa.

Osteoporosis

Note number and consistency of stools. If

constipation is a problem, Prescriber may
prescribe alternate or combination therapy
with a magnesium antacid or a laxative or
stool softener as necessary. Observe for S&S of
hypercalcemia in patients receiving frequent or
high doses. Monitor lab tests: Weekly serum and
urine calcium in patients receiving prolonged
therapy and in
patients with renal dysfunction

PO 80325 mg/day

Medication Log Rev 062013 SR

Mechanism of
Action

Reason/Indication for
Admin. for Your
Client

Nursing Implications

Medication Log Rev 062013 SR

Medication: Brand
and Generic Names
Recommended Dose,
Freq. and Route
metoprolol tartrate,
(Lopressor)
PO 25 mg/day (range
25-300 mg/day)

Classification

Prescribed
Dose

Prescribed
Freq.

Prescribed
Route

Antihypertensive

25mg

1 tab QAM
Mon.
Wed.
Fri.

PO

Beta-adrenergic antagonist
effect on beta receptors 1o
on cardiac muscle

Essential
Hypertension

cholecalciferol,
(Vitamin D 3)
PO 400-1000 IU Daily

Fat Soluble Vitamins

2000 IU

Q morning
and
bedtime

PO

Requires activation in the

liver and kidneys to create the
active form of vitamin D3
(calcitriol). Promotes the
intestinal absorption of
dietary calcium

Osteoporosis

memantine
(Namenda XR )
PO Initiate with 5 mg
once daily, increase
dose by 5 mg/wk. over
a 3-wk. period to
target dose of 10 mg
b.i.d.
carbidopa-levodopa
(Sinemet)
PO 1 tablet
containing 10
mg carbidopa/100 mg
levodopa
or 25 mg
carbidopa/100 mg
levodopa t.i.d.,
increased by
1 tablet daily or every
other day
up to 6 tablets/day

N-Methyl-DAspartate (NMDA)
Receptor Antagonist;
Antidementia

28mg

Every Day

PO/
DNC

Dementia CCE
w/Behavioral
Disturbance

Dopamine Receptor
Agonist;
Antiparkinson

25-100mg

QAM and
HS

PO

Blockade of NMDA receptors

by memantine may slow
intracellular calcium
accumulation, and help to
prevent further nerve damage
without interfering with the
physiological actions of
glutamate that are required
for memory and learning
Carbidopa prevents
peripheral metabolism
levodopa making
Levodopa available for
transport to brain.

Medication Log Rev 062013 SR

Mechanism of Action

Reason/Indication
for Admin. for Your
Client

Parkinsons

Nursing Implications

Take apical pulse and BP and report

significant rate, rhythm, or pulse quality
prior to adm drug. Monitor: BP, HR, ECG
during IV adm, I&O, daily wt, auscultate daily
for pulmonary rales, signs of mental
depression. Observe hypertensive CHF Pt.
closely for HF, DOE, orthopnea, edema, night
cough, distended neck veins. Take BP end of 12
h dosing interval evaluate adequacy
hypertension particularly 2 dose daily.
May take 1 wk. for maximum BP effect.
Assess for symptoms of vitamin deficiency
prior to and periodically during therapy.
Assess patient for bone pain and weakness
prior to and during therapy. Observe patient
carefully for evidence of hypocalcemia. Protect
symptomatic patient by raising and padding
side rails; keep bed in low position. Monitor
serum calcium, phosphorus, and alkaline
phosphatase labs. Serum calcium times
phosphate product (Ca X P) should not exceed
70 mg2 /dL2
Monitor respiratory and CV status, especially
with preexisting heart disease. Assess for and
report S&S of focal neurologic deficits (e.g.,
TIA, ataxia, vertigo). Lab tests: Periodic Hct &
Hgb, serum sodium, alkaline phosphatase, and
blood glucose. Monitor diabetics for loss of
glycemic control
Monitor vital signs, alterations in BP, pulse,
and respiratory rate and rhythm. Observe and
report promptly adverse reactions and
therapeutic effects: abnormal involuntary
movement such as facial grimacing,
exaggerated chewing, protrusion of tongue,
rhythmic opening and closing of mouth,
bobbing of head, jerky arm and leg
movements, exaggerated respiration, and
increase in bradykinesia. Monitor lab tests:
Periodic blood glucose, hepatic and renal
function tests, CBC with differential, Hgb and
Hct.

Medication: Brand
and Generic Names
Recommended Dose,
Freq. and Route

Classification

Prescribed
Dose

Prescribed
Freq.

Prescribed
Route

Mechanism of Action

Reason/Indication
for Admin. for Your
Client

Nursing Implications

ondansetron
hydrochloride
(Zofran)
PO/IV 4-8 mg 2-3
times a day

Gastrointestinal
Agent:
Selective serotonin
(5-HT3) receptor
antagonist

4mg

PRN q6hrs

PO

Binds with Serotonin

receptors in small intestine
blocking the vomiting
reflex.

Nausea:
hyperemesis
gravidarum

Monitor fluid and electrolyte status. Diarrhea,

which may cause fluid and electrolyte
imbalance, is a potential adverse effect of the
drug. Monitor cardiovascular status, especially
in patients with a history of coronary artery
disease. Rare cases of tachycardia and angina
have been reported.

nifedifine ER
(Procardia XL)
PO 1020 mg t.i.d. up
to 180 mg/day or
Extended release: 30
60 mg once/day

Antihypertensive:
Calcium Channel
Blocker

10 mg

Every Day

PO

Selectively blocks calcium ion

influx without changing serum
calcium concentrations
relaxing the muscles of the
heart and blood vessels.

Essential
Hypertension

Monitor fluid and electrolyte status.

Diarrhea, which may cause fluid and
electrolyte imbalance, is a potential adverse
effect of the drug. Monitor cardiovascular
status, especially in patients with a history of
coronary artery disease. Rare cases of
tachycardia and angina have been reported.

docusate sodium
(Colace)
PO 50500 mg/day
PR

Stool Softener

100 mg

Every Day
PRN

PO

Anionic surface-active agent

with emulsifying and wetting

Constipation

Withhold drug if diarrhea develops and notify

physician. Therapeutic effectiveness: Usually
apparent 13 d after first dose.

loperamide
(Imodium)
PO 4 mg followed by
2 mg after each
unformed stool (max:
16 mg/day)

Antidiarrheal

Q 6 hrs

PO

Loose Stool

Monitor therapeutic effectiveness.

Chronic diarrhea usually responds
within 10 days; if no improvement
within this time, it is unlikely that symptoms
will be controlled by further administration.
Monitor fluid and electrolyte balance. Monitor
GI symptoms (possible signs of potentially fatal
toxic megacolon).

Medication Log Rev 062013 SR

2 mg

properties.

Inhibits GI peristaltic activity.

Prolongs transit time of
intestinal contents,
increases consistency of stools,
and reduces fluid and
electrolyte loss